Illumina
Overview

Date:
10th June 2025, Tuesday

Time:
10:00 am - 11:00 am (Cape Town)
12:00 pm - 01:00 pm (Dubai)
01:30 pm – 02:30 pm (Delhi)
03:00 pm - 04:00 pm (Bangkok)
04:00 pm - 05:00 pm (Singapore)
05:00 pm - 06:00 pm (Seoul / Tokyo)
06:00 pm - 07:00 pm (Melbourne)

Register Now
We understand that our webinar timing may not suit your busy schedule. Please feel free to register to get the on-demand recording link once it is ready.

Implementing WHO recommendations for NGS in Drug-Resistant Tuberculosis (DR-TB) can seem like a complex journey. Looking for clarity and a clear path forward?

This webinar is part of a six-part webinar series which provides a practical roadmap and real-world guidance by showcasing the implementation journeys of pioneering national TB programs integrating targeted NGS into their TB testing algorithms. In this webinar, Namibia- in the integration phase, will share their experience of pioneering their national TB program.

This focused 30-minute webinar delivers specific stories and lessons learned aligned with these implementation stages, offering a comprehensive understanding of the process and the tangible impact of NGS on DR-TB control.

Gain practical insights to accelerate your End TB goals by learning directly from the pioneering experts leading this transformative change. Ready to translate WHO recommendations into actionable strategies? Register now for the whole six-part webinar series.

In this series, you will discover:

  • The key drivers and infrastructure considerations for adopting tNGS in diverse national settings.
  • Understanding of national models for NGS-enhanced TB testing algorithms.
  • Real-world impact and best practices for successful tNGS implementation.

Speaker:

Dr Nunurai Ruswa
Chief Medical Officer (Acting, TB and Leprosy)
Ministry of Health & Social Services (MoHSS), Namibia

Dr Nunurai Ruswa is a medical doctor with extensive experience working in high burden settings for infectious diseases, particularly tuberculosis (TB) and HIV. His main expertise is in coordinating both the clinical and programmatic aspects of TB and HIV, with his main focus being drug resistant TB as well as TB/HIV. His experience spans work at community level, clinical level and national programme management level. He is also currently an executive committee member in the Namibia HIV Clinicians Society, responsible for coordinating guidelines development and capacity building on HIV management in both the private and public health sectors in Namibia.

Prof Emmanuel Nepolo
Associate Professor, Department of Biomedical and Translational Sciences
School of Medicine, University of Namibia

Emmanuel Nepolo is an Associate Professor and a Biomedical Research Scientist at the University of Namibia, School of Medicine. He dedicated his professional and scientific research work on the training, laboratory infrastructure development and application of sequencing technology to fight against resistant tuberculosis and other pathogens of public health interests such COVID-19, Malaria and HIV/AIDS. His research work focuses on local and global transmission dynamics, resistance and compensatory mechanisms, population structure and evolution, virulence/physiology/pathobiology of mycobacteria, high-throughput technologies in research and diagnostics, implementation of new technologies in high incidence countries, individualized therapy and evolutionary medicine.
Register below to join us at the webinar.
Company Legal
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.